Michael Ulz
Stock Analyst at Baird
(4.04)
# 472
Out of 4,851 analysts
115
Total ratings
50%
Success rate
12.78%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Ulz
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
KPTI Karyopharm Therapeutics | Maintains: Outperform | $54 → $42 | $4.25 | +888.24% | 6 | May 13, 2025 | |
SLN Silence Therapeutics | Maintains: Overweight | $45 → $25 | $5.41 | +362.11% | 12 | May 9, 2025 | |
VKTX Viking Therapeutics | Maintains: Overweight | $105 → $102 | $26.61 | +283.31% | 3 | Apr 24, 2025 | |
ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $284 → $268 | $303.77 | -11.78% | 10 | Apr 11, 2025 | |
KYTX Kyverna Therapeutics | Maintains: Overweight | $40 → $20 | $2.79 | +616.85% | 2 | Apr 1, 2025 | |
CABA Cabaletta Bio | Maintains: Overweight | $30 → $22 | $2.18 | +909.17% | 6 | Apr 1, 2025 | |
AARD Aardvark Therapeutics | Initiates: Overweight | $29 | $11.66 | +148.71% | 1 | Mar 10, 2025 | |
YMAB Y-mAbs Therapeutics | Maintains: Underweight | $11 → $7 | $4.88 | +43.44% | 7 | Mar 5, 2025 | |
IOVA Iovance Biotherapeutics | Maintains: Outperform | $24 → $20 | $1.82 | +998.90% | 4 | Feb 28, 2025 | |
THRD Third Harmonic Bio | Downgrades: Equal-Weight | $20 → $5 | $5.25 | -4.76% | 5 | Feb 12, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $10 | $1.95 | +412.82% | 2 | Feb 3, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $46 → $96 | $51.68 | +85.76% | 4 | Jan 28, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $52 | $13.27 | +291.86% | 2 | Aug 14, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $110 → $115 | $127.60 | -9.87% | 9 | Jul 12, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $57 | $45.29 | +25.86% | 3 | Jun 18, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $36 → $27 | $16.61 | +62.55% | 4 | May 13, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $7 | $1.36 | +414.71% | 8 | Feb 27, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $45 → $48 | $34.76 | +38.09% | 4 | Nov 3, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $27 | $8.40 | +221.43% | 2 | Aug 16, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $20 | $3.15 | +534.92% | 3 | Mar 24, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $2.96 | +1,420.27% | 1 | Feb 1, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $10 | $0.68 | +1,379.51% | 3 | Jan 27, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $3 | $2.78 | +7.91% | 1 | Jan 27, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $18 → $30 | $5.23 | +473.61% | 1 | Jan 27, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $25 → $30 | $1.25 | +2,309.64% | 3 | Mar 30, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $10.11 | +345.32% | 1 | Oct 8, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $20 | $0.35 | +5,633.94% | 2 | May 28, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $80 | $36.40 | +119.78% | 3 | Nov 3, 2017 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $15 | $6.27 | +139.43% | 3 | Jul 12, 2017 |
Karyopharm Therapeutics
May 13, 2025
Maintains: Outperform
Price Target: $54 → $42
Current: $4.25
Upside: +888.24%
Silence Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $45 → $25
Current: $5.41
Upside: +362.11%
Viking Therapeutics
Apr 24, 2025
Maintains: Overweight
Price Target: $105 → $102
Current: $26.61
Upside: +283.31%
Alnylam Pharmaceuticals
Apr 11, 2025
Maintains: Equal-Weight
Price Target: $284 → $268
Current: $303.77
Upside: -11.78%
Kyverna Therapeutics
Apr 1, 2025
Maintains: Overweight
Price Target: $40 → $20
Current: $2.79
Upside: +616.85%
Cabaletta Bio
Apr 1, 2025
Maintains: Overweight
Price Target: $30 → $22
Current: $2.18
Upside: +909.17%
Aardvark Therapeutics
Mar 10, 2025
Initiates: Overweight
Price Target: $29
Current: $11.66
Upside: +148.71%
Y-mAbs Therapeutics
Mar 5, 2025
Maintains: Underweight
Price Target: $11 → $7
Current: $4.88
Upside: +43.44%
Iovance Biotherapeutics
Feb 28, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $1.82
Upside: +998.90%
Third Harmonic Bio
Feb 12, 2025
Downgrades: Equal-Weight
Price Target: $20 → $5
Current: $5.25
Upside: -4.76%
Feb 3, 2025
Maintains: Overweight
Price Target: $18 → $10
Current: $1.95
Upside: +412.82%
Jan 28, 2025
Maintains: Overweight
Price Target: $46 → $96
Current: $51.68
Upside: +85.76%
Aug 14, 2024
Maintains: Overweight
Price Target: $48 → $52
Current: $13.27
Upside: +291.86%
Jul 12, 2024
Maintains: Equal-Weight
Price Target: $110 → $115
Current: $127.60
Upside: -9.87%
Jun 18, 2024
Maintains: Overweight
Price Target: $53 → $57
Current: $45.29
Upside: +25.86%
May 13, 2024
Maintains: Equal-Weight
Price Target: $36 → $27
Current: $16.61
Upside: +62.55%
Feb 27, 2024
Maintains: Equal-Weight
Price Target: $3 → $7
Current: $1.36
Upside: +414.71%
Nov 3, 2023
Maintains: Equal-Weight
Price Target: $45 → $48
Current: $34.76
Upside: +38.09%
Aug 16, 2023
Maintains: Outperform
Price Target: $15 → $27
Current: $8.40
Upside: +221.43%
Mar 24, 2023
Maintains: Equal-Weight
Price Target: $30 → $20
Current: $3.15
Upside: +534.92%
Feb 1, 2023
Initiates: Overweight
Price Target: $45
Current: $2.96
Upside: +1,420.27%
Jan 27, 2023
Maintains: Overweight
Price Target: $20 → $10
Current: $0.68
Upside: +1,379.51%
Jan 27, 2023
Downgrades: Equal-Weight
Price Target: $3
Current: $2.78
Upside: +7.91%
Jan 27, 2023
Upgrades: Equal-Weight
Price Target: $18 → $30
Current: $5.23
Upside: +473.61%
Mar 30, 2022
Maintains: Equal-Weight
Price Target: $25 → $30
Current: $1.25
Upside: +2,309.64%
Oct 8, 2020
Initiates: Outperform
Price Target: $45
Current: $10.11
Upside: +345.32%
May 28, 2020
Maintains: Outperform
Price Target: $12 → $20
Current: $0.35
Upside: +5,633.94%
Nov 3, 2017
Maintains: Outperform
Price Target: $85 → $80
Current: $36.40
Upside: +119.78%
Jul 12, 2017
Maintains: Outperform
Price Target: $12 → $15
Current: $6.27
Upside: +139.43%